We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Phathom Pharmaceuticals Inc (PHAT) USD0.0001

Sell:$10.15 Buy:$10.17 Change: $0.17 (1.72%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Change: $0.17 (1.72%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Change: $0.17 (1.72%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Contact details

100 Campus Drive, Suite 102
United States
+1 (302) 6365400

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$606.88 million
Shares in issue:
57.25 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Michael Cola
    Independent Chairman of the Board
  • Terrie Curran
    President, Chief Executive Officer, Director
  • Azmi Nabulsi
    Co-Founder, Chief Operating Officer
  • Molly Henderson
    Chief Financial Officer and Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.